Posted by Michael Wonder on 15 Dec 2022
Avatrombopag maleate for the treatment of patients with primary chronic immune thrombocytopenia
15 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of avatrombopag maleate in the NHS in England.
Avatrombopag maleate is recommended as an option for the treatment of adults with primary chronic immune thrombocytopenia that is refractory to other treatments (for example, corticosteroids, immunoglobulins).
